Professor Rachelle Sampson and collaborators explore how personal transformative experiences, particularly psychedelic ones, can shape a new form of leadership called emergent leadership that fosters collective intelligence for societal problem-solving.
Bennet A Zelner
Universities and companies are claiming intellectual property on psychedelic compounds, sparking dialogue on how patents may impact innovation and access to care in the psychedelic ecosystem. Explore economic and cultural
Jonathan Sporn, Sisi Li, Graham Pechenik, Retsina Meyer, Anne Donohoe
Commercial investment dominates psychedelic sector funding, primarily for drug discovery. Non-commercial projects need financial backing for drug policy reform, public health education, harm reduction, and diversity initiatives. Strategic funding can
Daniel Goldberg, Andrew Chomer, Lindsay Hoover, Sasha Cohen
Panel: New psychedelic entrepreneurs discuss unique business structures and financial strategies aligning with values and purpose, rejecting traditional models for innovative, purpose-driven for-profit ventures.
Daniel Tarockoff, Scarlet Masius
Indigenous communities are key to the emerging psychedelic industry but often see little benefit. How can companies ensure their inclusion and fair share in the growing market? Join the conversation.
Jeeshan Chowdhury, David Heldreth, Julia Mande
Panel on regulatory obstacles in psychedelic therapy research: Leaders from the industry discuss challenges with policymakers and predict future developments in the field.
Tadeusz Hawrot, Natasia Poinsatte, Nicole Howell
Psychedelic businesses have rapidly emerged on American and Canadian exchanges, creating a multibillion dollar market. Industry insiders discuss challenges and predictions for psychedelic public companies.
Patrick Trucchio, Florian Brand, George Tziras, Tim Chang
Visionaries in Colorado and Oregon are shaping new psychedelic eco-systems by teaching, educating, and building businesses and nonprofits. Dreams are becoming reality in these emerging landscapes.
Jamie Beachy, Steve Elfrink, Martha Hammel, Nate Howard, Meaghan Len Richmond, Barine Majewska
Dr. Bennett explores the expanding field of ketamine treatment, covering current trends, controversies, and potential topics like enantiomers, mail order platforms, provider training, economics, and FDA approval challenges.
Commander Gunn, a USPHS officer and FDA Investigator, specializes in international inspections of drug, biologic, and device trial sponsors and study sites. With 13 years of experience, he previously held
Commander Gene Gunn
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.